Get started

PHARMA

ABBV BreakoutHuge breakout for ABBV closing the day above the double top formed from 2014/2015 highs between 70.70 and 71.60, both offering little resistance. RSI pushing into the high 80s shows good strong move up in my opinion, I won't be using RSI for short/sell/TP signal, rather buy more when it dips to over-sold territory on consolidation in the next few weeks... if that even happens. MACD indicator has room to continue upwards, watching MACD and EMA 20/50/200 crosses for a close trade signal. ABBV is still a strong buy for me. I went long after the previous longer term channel break near 70.10 last week, stop loss around 71.40 currently. GLHF!
NYSE:ABBVLong
by Dank-Traders
$CTRV 1st Conference Starts Tmrw Continues in the Right DrtnNothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months: Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Noble Financial reaffirmed a “Buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st. Teachers Advisors LLC boosted its position by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares worth $1,820,000 Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares worth $3,626,000 after buying an additional 189,634 shares during the last quarter. Geode Capital Management LLC boosted its position by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares worth $626,000 after buying an additional 7,057 shares during the last quarter. Morgan Stanley boosted its position in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares worth $493,000 after buying an additional 1,119 shares during the last quarter. 5.49% of the stock is owned by institutional investors. Very nice averages stakes taken by numerous groups and this is a month or two before the conferences. Shows some agencies might have gotten a sneak peak at the upcoming info. $CTRV
CLong
by StockGuild
Newest Alert is $CBIO$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million. Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months. Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017 Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows: Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS) Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments: Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor Anticipated Milestones CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
CLong
by StockGuild
Lupin is a Good Buy at current levels!Lupin is one of the top Pharma companies with an excellent Balance Sheet, Sales Revenue growth and a very good future. From long term investment point of view, this is an excellent company to have in your portfolio and current levels of 1250 are an excellent entry. One can add more if it dips further as this stock itself promises to give 20% + returns within or much before an year.. Technically.. Weekly charts shows Fibonacci retracements to 50% and good chances of a bounce from here very soon...
NSE:LUPINLong
by traderparag
$1.25 Price target (65k shares)2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well and benefit from the repeal of Obamacare. This will be one to watch, lock in profits don't get emotional. Good money to be made long term.
OTC:VDRMLong
by Cryptocol